HIV Disease Progression Clinical Trial
Official title:
Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
All participants in the REVIVE trial will be randomized (1:1) at the time of study entry to receive azithromycin prophylaxis or placebo for 28 days and will be followed for 24 weeks to determine the primary outcome measure. Total follow up duration will be 48 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05584397 -
Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
|
||
| Completed |
NCT01299948 -
Progression of HIV-Disease Under Low Dose Corticosteroids
|
Phase 2 | |
| Recruiting |
NCT05688709 -
Acceptability, Feasibility and Effectiveness of Online Peer Support Group for ART Adherence Among Youth
|
N/A | |
| Completed |
NCT05383456 -
The Visceral Adiposity Measurement and Observation Study
|